Grace Therapeutics, Inc 10-Q/A, filed Feb 19, 2025
Grace Therapeutics, Inc. (GRCE)
10-Q/A
2025-02-19
For: 2024-12-31
View Original
Added on
April 11, 2026
About this 10-Q/A
Grace Therapeutics, Inc filed this 10-Q/A on February 19, 2025, covering the quarter ended December 31, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
For the quarterly period ended December 31, 2024
or
For the transition period from to
Commission file number: 001-35776
(Exact name of registrant as specified in its charter)
|
State of
|
|
|
|
(State or other jurisdiction of incorporation or
organization)
|
|
(I.R.S. Employer Identification Number)
|
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every
Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
|
|
☒
|
|
Smaller reporting company
|
|
|
Emerging growth company
|
☐
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes ☐ No ☒
The number of outstanding shares of common stock of the registrant, par value per
share of $0.0001, as of February 12, 2025, was 13,416,735 .
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-Q/A (the “Amendment”) is being filed solely to correct the number of shares of common stock outstanding on the cover page of the
registrant’s Form 10-Q for the period ended December 31, 2024 (the “Original Filing”) filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2025. No other changes have been made to the Original Filing, whether to update
the Original Filing to reflect events occurring subsequent to the filing of the Original Filing or otherwise. As required by Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Form 10-Q/A contains new certifications by the
registrant’s principal executive officer and principal financial officer, which are being filed as exhibits to this Form 10-Q/A. Because this Form 10-Q/A includes no financial statements, the registrant is not including certifications pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
Item 6. Exhibits
|
Exhibit No.
|
Description
|
|
|
|
|
|
|
|
Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by referenced to Exhibit 3.3 on the Current Report on Form 8-K filed with
the Commission on October 7, 2024)
|
|
|
|
|
|
|
|
Certificate of Amendment to the Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by referenced to Exhibit 3.1 on the
Current Report on Form 8-K filed with the Commission on October 28, 2024)
|
|
|
|
|
|
|
|
Bylaws of Grace Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 on the Current Report on Form 8-K filed with the Commission on
October 28, 2024)
|
|
|
|
|
|
|
|
Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on the Quarterly Report on Form 10-Q filed with
the Commission on February 13, 2025)
|
|
|
|
|
|
|
|
Form of 2024 Incentive Stock Option Award Agreement under the Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to
Exhibit 10.2 on the Quarterly Report on Form 10-Q filed with the Commission on February 13, 2025)
|
|
|
|
|
|
|
|
Form of 2024 Non-Qualified Stock Option Award Agreement under Grace Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to
Exhibit 10.3 on the Quarterly Report on Form 10-Q filed with the Commission on February 13, 2025)
|
|
|
|
|
|
|
10.4†
|
|
Form of Indemnification Agreement between Acasti Pharma Inc. and its directors and officers (incorporated by reference to Exhibit 10.1 to the
Company’s Registration Statement on Form S-4 filed with the Commission on June 27, 2024)
|
|
|
|
|
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
|
|
|
|
|
|
|
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
|
|
|
|
|
|
|
|
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 (incorporated by reference to Exhibit 32.1 on the Quarterly Report on Form 10-Q filed with the Commission on February 13, 2025)
|
|
|
|
|
|
|
|
Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (incorporated by reference to Exhibit 32.2 on the Quarterly Report on Form 10-Q filed with the Commission on February 13, 2025)
|
|
|
|
|
|
|
101.INS
|
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the
Inline XBRL document
|
|
|
|
|
|
101.SCH
|
|
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
|
|
|
|
|
| 101.LAB |
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
|
|
| 101.PRE |
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
|
|
|
104
|
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
|
* Filed or furnished herewith.
** Previously furnished with the Quarterly Report on Form 10-Q for the period ended December 31, 2024 filed with the SEC on February 13, 2025.
† Indicates a management contract or compensatory plan.
# Previously filed with the Quarterly Report on Form 10-Q for the period ended December 31, 2024 filed with the SEC on February 13, 2025 solely to reflect the name
change of the Company from Acasti Pharma Inc. to Grace Therapeutics, Inc.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
Dated: February 18, 2025
|
|
|
|
|
|
|
|
|
GRACE THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Prashant Kohli
|
|
|
|
Name: Prashant Kohli
|
|
|
|
Title: Chief Executive Officer (Principal Executive Officer)
|
|
|
|
|
|
|
By:
|
/s/ Robert DelAversano
|
|
|
|
Name: Robert DelAversano
|
|
|
|
Title: Principal Financial Officer (Principal Financial Officer)
|
Exhibit 31.1
CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Prashant Kohli, certify that:
1. I have reviewed this quarterly report on Form 10-Q/A of Grace Therapeutics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|
Date: February 18, 2025
|
|
|
|
|
|
/s/ Prashant Kohli
|
|
|
Chief Executive Officer
|
|
Exhibit 31.2
CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert DelAversano, certify that:
1. I have reviewed this quarterly report on Form 10-Q/A of Grace Therapeutics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|
Date: February 18, 2025
|
|
|
|
|
|
/s/ Robert DelAversano
|
|
|
Principal Financial Officer
|
|